S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
NASDAQ:AERI

Aerie Pharmaceuticals (AERI) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$15.25
▼
$15.25
50-Day Range
$15.18
▼
$15.25
52-Week Range
$4.81
▼
$15.37
Volume
600 shs
Average Volume
974,748 shs
Market Capitalization
$753.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

AERI stock logo

About Aerie Pharmaceuticals (NASDAQ:AERI) Stock

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.


AERI Stock News Headlines

September 25, 2023 | uk.finance.yahoo.com
Rising Glaucoma Cases Forecast a Strong Optic Nerves Disorder Treatment Market
September 13, 2023 | benzinga.com
Optic Nerves Disorder Treatment Market Rises: North America Takes the Helm
September 26, 2023 | Chaikin Analytics (Ad)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
August 25, 2023 | time.com
Aerie Promo Codes
August 24, 2023 | uk.finance.yahoo.com
Angina Pectoris Drugs Global Market Report 2023
August 24, 2023 | uk.finance.yahoo.com
Ocular Hypertension Treatment Global Market Report 2023
July 18, 2023 | msn.com
Alcon (ALC) Gains From Robust Contact Lense Sales, Launches
June 27, 2023 | finance.yahoo.com
VillageMD Welcomes Richard Rubino as Chief Financial Officer
September 26, 2023 | Chaikin Analytics (Ad)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
June 22, 2023 | marketwatch.com
The Glaucoma Therapeutics market's size, share, and revenue will be thoroughly examined, with an anticipated CAGR of 13% increase from 2023 to 2030.
June 22, 2023 | uk.finance.yahoo.com
I-Mab Announces the Appointment of Raj Kannan as CEO
June 22, 2023 | markets.businessinsider.com
I-Mab Names Raj Kannan CEO - Quick Facts
June 8, 2023 | uk.finance.yahoo.com
Ophthalmic Drugs Global Market Report 2023
May 17, 2023 | msn.com
Alcon (ALC) Vision Care Sales Robust, Margin Pressure Persists
May 17, 2023 | marketwatch.com
Glaucoma Therapeutics Market Size and Growth Analysis 2023-2031 by Absolute Reports with [121 Pages] in Pharmaceuticals Sector
May 17, 2023 | marketwatch.com
Optic Nerves Disorder Treatment Market Size Fundamentals And Forecast Analysis 2023-2030
May 16, 2023 | marketwatch.com
Ophthalmology Therapeutics Market 2023: Global Opportunity Analysis by Revenue, Gross Margin, Market Share
May 5, 2023 | marketwatch.com
2030 Vision: Ophthalmology Drugs Market Value to Hit New Heights
May 5, 2023 | marketwatch.com
Anophthalmia and Microphthalmia Treatment Market Share, Size and Value Analysis with growing 5.3% CAGR during period 2023 to 2030
May 4, 2023 | marketwatch.com
Glaucoma Therapeutics Market Trend Analysis, Future Demand, Updates (2023-2030)
May 4, 2023 | marketwatch.com
Rho Kinases Inhibitor Market 2023 Precise Outlook – Kowa Pharmaceuticals, Senju Pharmaceutical, Novartis AG, AERIE PHARMACEUTICALS
May 2, 2023 | uk.news.yahoo.com
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
May 2, 2023 | marketwatch.com
Glaucoma Treatment Market Upcoming Trends, Size, Key Players, Revenue, Share, and Forecast 2023 to 2031
April 28, 2023 | marketwatch.com
Wave-Front Aberrometer Market Research 2023 Growth, Trends, Outlook and Future Scope Analysis 2031
April 27, 2023 | marketwatch.com
Glaucoma and Dry Eye Diseases Market Research Analysis 2023-2031
April 27, 2023 | marketwatch.com
2023 to 2030, Rho Associated Protein Kinase 2 Market Demand
April 26, 2023 | thestreet.com
Aerie Pharma Falls on Glaucoma Eye Drop Safety Concerns
See More Headlines
Receive AERI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AERI Company Calendar

Last Earnings
11/04/2021
Today
9/26/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AERI
CUSIP
N/A
CIK
1337553
Web
www.aeriepharma.com
Phone
(919) 237-5300
Fax
949-526-8787
Employees
376
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.77)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-74,810,000.00
Net Margins
-17.09%
Pretax Margin
-16.47%
Return on Equity
N/A
Return on Assets
-2.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.27
Quick Ratio
1.92

Sales & Book Value

Annual Sales
$194.13 million
Price / Sales
3.88
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.32) per share
Price / Book
-4.59

Miscellaneous

Outstanding Shares
49,417,000
Free Float
47,223,000
Market Cap
$753.61 million
Optionable
Optionable
Beta
-0.06
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Raj Kannan (Age 58)
    CEO, Principal Financial Officer & Director
    Comp: $753.49k
  • Dr. Casey C. Kopczynski Ph.D. (Age 61)
    Co-Founder, Chief Innovation Officer & Head of Research and External Innovation
    Comp: $685.06k
  • Mr. John W. LaRocca Esq. (Age 57)
    Gen. Counsel & Sec.
    Comp: $676.62k
  • Mr. Peter F. Lang (Age 50)
    Chief Financial Officer
  • Dr. Michelle Senchyna Ph.D.
    Head of Clinical Devel. & Operations
  • Mr. Jeffrey M. Calabrese CPA (Age 55)
    VP of Fin. & Principal Accounting Officer
  • Ms. Carolyn McAuliffe
    Sr. Director of Communications
  • Ms. Wanda Francies
    Head of HR
  • Mr. Marvin J. Garrett (Age 71)
    Head of Regulatory Affairs & Quality Assurance
  • Mr. Craig R. Skenes
    Head of Bus. Devel.

Key Competitors

View All Competitors













AERI Stock - Frequently Asked Questions

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced its earnings results on Thursday, November, 4th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.62) by $0.10. The firm earned $29.31 million during the quarter, compared to the consensus estimate of $29.13 million. During the same period in the previous year, the company earned ($0.65) EPS.

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

What is Aerie Pharmaceuticals' stock price today?

One share of AERI stock can currently be purchased for approximately $15.25.

How much money does Aerie Pharmaceuticals make?

Aerie Pharmaceuticals (NASDAQ:AERI) has a market capitalization of $753.61 million and generates $194.13 million in revenue each year. The company earns $-74,810,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

How many employees does Aerie Pharmaceuticals have?

The company employs 376 workers across the globe.

How can I contact Aerie Pharmaceuticals?

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The official website for the company is www.aeriepharma.com. The company can be reached via phone at (919) 237-5300, via email at abavishi@aeriepharma.com, or via fax at 949-526-8787.

This page (NASDAQ:AERI) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -